Search

You searched for "Tanzania"

11 results found

Delivering a trainee-led Urolink educational programme – my experience in Tanzania

1 March 2024 | | URO - Andrology, URO - Basic Science Research, URO - Endourology & Stones, URO - Functional / Reconstructive Urology, URO - Infection, URO - Neurourology, URO - Paediatric Urology, URO - Trauma & Emergency, URO - Urologic Oncology, URO - Uroradiology, URO - Technology
In May 2023, I travelled to Moshi, Tanzania, where I visited Kilimanjaro Christian Medical Centre (KCMC) – a trip which was made possible through the collaborative efforts of the British Association of Urological Surgeons (BAUS) Urolink and with the support...

The Lester Eshleman Urology Workshop (Tanzania): a trainee’s perspective

1 May 2014 | | URO - Core Urology
For many trainees a period abroad is increasingly an essential supplement to higher surgical training in the UK. However, for many, because of family responsibilities or financial imperatives, this is not always a viable option. There are however alternatives. Here...

The value of Urolink: an OOPE experience

1 May 2019 | | URO - Core Urology
I was fortunate enough to be able to take some time out of my training after ST5 to pursue an Out Of Programme Experience (OOPE) year. During the Urolink meeting at the British Association of Urological Surgeons (BAUS) 2017 conference...

The Welsh Urological Society (WUS)

24 January 2019 -25 January 2019 | Andrology
By Thomas Ellul, Specialist Registrar in Urology, Wales Deanery. The New Year brings with it the opportunity for urologists in Wales to congregate and discuss the events of the previous year as well as current research, guidelines and hot topics....

The multidisciplinary team meeting: London calling!

1 January 2015 | | URO - Technology
The multidisciplinary team meeting, or MDT, is the foundation of cancer management in the UK. The MDT consists of a group of experts in different fields of medicine and surgery coming together at regular intervals to discuss the diagnosis and...

Bladder cancer – an overshadowed ‘volcano’

1 May 2015 | | URO - Urologic Oncology
Bladder cancer has often been overshadowed by the limelight of prostate cancer. However, of all the urological cancers, bladder cancer is the only one which has shown a slight decline in age-standardised five-year survival rates over the last couple of...

Post CCT fellowship in genitourethral reconstruction at St George’s Hospital: an experience unique to the UK

1 July 2018 | | URO - Core Urology
I first developed an interest in genitourethral reconstruction, particularly urethroplasty, at the beginning of my urology training. Working in Bristol and Weston Super Mare for David Dickerson inspired me to develop this further. Mr Dickerson performs one of the largest...

In conversation with Sarika Nalagatla

29 June 2023 | | URO - Core Urology
We were delighted to catch up with Sarika Nalagatla, new Chair of the BAUS Section of Trainees (BSoT) about her life as a trainee urologist and plans for the association. Can you tell us a little bit about what led...

The impact of FGM on the genitourinary system: a 2021 perspective

3 March 2021 | | URO - Functional / Reconstructive Urology, URO - Trauma & Emergency
Awareness of female genital mutilation (FGM) in European countries has increased over recent decades as a result of globalisation and migration of populations. The World Health Organization (WHO) describes FGM as procedures that involve partial or total removal of the...

Sexual dysfunction following prostate cancer treatment

4 March 2024 | | URO - Andrology, URO - Urologic Oncology
Prostate cancer is common with over 52,300 new cases diagnosed annually in the UK; this is expected to rise by 15% between 2023-2025 and 2038-2040 [1]. Radical prostatectomy continues to be the most common form of radical treatment for men...

Trials offering cytoreductive surgery for men with de novo synchronous metastatic prostate cancer

8 November 2021 | | URO - Basic Science Research, URO - Urologic Oncology
Life expectancy in men diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) has risen to a median of 4.8 years with upfront systemic agents (such as docetaxel) in addition to standard androgen deprivation therapy (ADT) [1-3]. Within this...